NCT07144735View on ClinicalTrials.gov

Allogeneic γδT Cells in Glioblastoma

NARecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2030

Conditions
Glioblastoma (GBM)Glioblastoma Multiforme (GBM)
Interventions
DRUG

Allogeneic γδ T (ABOUT) cells

Allogeneic γδ T cells genetically edited to knockout the ARIH1 and BCL11b genes.

Trial Locations (3)

100191

RECRUITING

Peking University Third Hospital, Beijing

450052

RECRUITING

Zhengzhou Second Hospital, Zhengzhou

451162

RECRUITING

Henan Academy of Innovations in Medical Science, Zhengzhou

Sponsors

Collaborators (1)

Changping Laboratory
All Listed Sponsors
collaborator

Peking University

OTHER

collaborator

Changping Laboratory

OTHER

lead

Peking University Third Hospital

OTHER

NCT07144735 - Allogeneic γδT Cells in Glioblastoma | Biotech Hunter | Biotech Hunter